Aclaris Therapeutics Inc [ACRS] stock is trading at $1.52, up 9.35%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ACRS shares have gain 5.56% over the last week, with a monthly amount glided 20.63%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Aclaris Therapeutics Inc [NASDAQ: ACRS] stock has seen the most recent analyst activity on May 28, 2025, when Wedbush initiated its Outperform rating and assigned the stock a price target of $8. On December 23, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $20 on the stock. Cantor Fitzgerald upgraded its rating to a Overweight. Leerink Partners upgraded its rating to a Outperform and raised its price target to $7 on November 19, 2024. Jefferies upgraded its rating to Buy for this stock on November 19, 2024, and upped its price target to $7. In a note dated November 19, 2024, BTIG Research upgraded an Buy rating on this stock but restated the target price of $8.
Aclaris Therapeutics Inc [ACRS] stock has fluctuated between $1.05 and $5.17 over the past year. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Aclaris Therapeutics Inc [NASDAQ: ACRS] shares were valued at $1.52 at the most recent close of the market. An investor can expect a potential return of 607.24% based on the average ACRS price forecast.
Analyzing the ACRS fundamentals
Aclaris Therapeutics Inc [NASDAQ:ACRS] reported sales of 17.78M for the trailing twelve months, which represents a drop of -39.32%. Gross Profit Margin for this corporation currently stands at 0.21% with Operating Profit Margin at -7.92%, Pretax Profit Margin comes in at -7.32%, and Net Profit Margin reading is -7.32%. To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is -0.92 and Total Capital is -0.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4333 points at the first support level, and at 1.3467 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5633, and for the 2nd resistance point, it is at 1.6067.
Ratios To Look Out For
For context, Aclaris Therapeutics Inc’s Current Ratio is 5.06. Also, the Quick Ratio is 5.06, while the Cash Ratio stands at 1.41. Considering the valuation of this stock, the price to sales ratio is 9.26, the price to book ratio is 1.14.
Transactions by insiders
Recent insider trading involved Mehra Anand, Director, that happened on Nov 19 ’24 when 0.67 million shares were purchased. 10% Owner, Leonard Braden Michael completed a deal on Aug 05 ’24 to buy 0.21 million shares. Meanwhile, 10% Owner Leonard Braden Michael bought 0.17 million shares on Aug 02 ’24.
